The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to
immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to …

Molecular proximity orchestrates biological function, and blocking existing proximities is an
established therapeutic strategy. By contrast, strengthening or creating neoproximity with …

Radiation therapy is a mainstay of cancer treatment but does not always lead to complete
tumor regression. Here we combine radiotherapy with blockade of the 'don't-eat-me'cell …

Antibody responses during infection and vaccination typically undergo affinity maturation to
achieve high-affinity binding for efficient neutralization of pathogens,. Similarly, high affinity …

Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …

The development of neoplasia involves a complex and continuous interplay between
malignantly transformed cells and the tumour microenvironment (TME). Cancer …

During the past decade there has been a revolution in cancer therapeutics by the
emergence of antibody-based and cell-based immunotherapies that modulate immune …

Multiple studies have confirmed that programmed cell death 1/programmed cell death ligand-
1 (PD-1/PD-L1) and immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 play pivotal …

The spatial distribution of cell surface proteins governs vital processes of the immune system
such as intercellular communication and mobility. However, fluorescence microscopy has …

Fibrosis is a pathological tissue repair activity in which many myofibroblasts are activated
and extracellular matrix are excessively accumulated, leading to the formation of permanent …